All In Biotech

Drug Trial Radar · NCT02682511

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

34

Planned (sponsor's estimate)

Start

Jan 2017

Primary completion

Mar 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Cumberland PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).

Conditions

  • Scleroderma, Diffuse
  • Scleroderma, Systemic
  • Scleroderma, Limited
  • Sclerosis, Progressive Systemic
  • Skin Diseases
  • Connective Tissue Diseases
  • Pathologic Processes
  • Autoimmune Diseases

Interventions

  • Oral IfetrobanDrug

    Subjects will be treated with oral ifetroban or placebo daily for 365 days

  • Oral PlaceboDrug

    Subjects will be treated with oral ifetroban or placebo daily for 365 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs) and Serious AEs (SAEs)Time frame: 56 weeks

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • The Universtity of Arizona Arthrtis Center

    Tucson, Arizona

  • UCLA

    Los Angeles, California

  • Cleveland Clinic - Florida

    Weston, Florida

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Hospital for Special Surgery

    New York, New York

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Baylor Research Institute

    Dallas, Texas

  • PGIMER

    Chandigarh, Chandigarh, India

  • KDH - Kokilaben Dhirubhai Ambani Hospital

    Mumbai, Maharashtra, India

  • B. J. Government Medical College

    Pune, Maharashtra, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.